• No results found

[PDF] Top 20 Formulation Development and Evaluation of Venlafaxine HCL Buccal Patch

Has 10000 "Formulation Development and Evaluation of Venlafaxine HCL Buccal Patch" found on our website. Below are the top 20 most common "Formulation Development and Evaluation of Venlafaxine HCL Buccal Patch".

Formulation Development and Evaluation of Venlafaxine HCL Buccal Patch

Formulation Development and Evaluation of Venlafaxine HCL Buccal Patch

... Buccal patches containing drug reservoir was prepared by solvent casting methods. PVP was used as mucoadhesive polymer and propylene glycol (30-50% of the polymer weight) as plasticizer. Acetic acid 1% v/v ... See full document

5

FORMULATION DEVELOPMENT AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE ORODISPERSIBLE TABLETS

FORMULATION DEVELOPMENT AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE ORODISPERSIBLE TABLETS

... Over a decade, the demand for development of orally disintegrating tablets (ODTs) has enormously increased as it has significant impact on the patient compliance. Orally disintegrating tablets offer an advantage ... See full document

9

FORMULATION DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF LIQUISOLID TABLET CONTAINING PIOGLITAZONE HCL

FORMULATION DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF LIQUISOLID TABLET CONTAINING PIOGLITAZONE HCL

... complexing agents such as cyclodextrins, the use of surfactants or co-solvents and the synthesis of pro- drugs. [3] Over past few decades, various approaches have been introduced to solve the problem of ... See full document

9

FORMULATION DEVELOPMENT AND EVALUATION OF BUCCAL FILMS OF CARVEDILOL

FORMULATION DEVELOPMENT AND EVALUATION OF BUCCAL FILMS OF CARVEDILOL

... from buccal patches for different formulations through porcine buccal membrane was mounted over a K-C Cell whose internal diameter is ...a buccal patch was placed over it so as to secure the ... See full document

8

FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF ALENDRONATE BUCCAL TABLETS

FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF ALENDRONATE BUCCAL TABLETS

... mucoadhesive buccal tablet for the buccal delivery of the alendronate via buccal ...mucosa. Buccal tablets of alendronate are designed to release drug at mucosal site for extended period of ... See full document

7

Formulation Development and Evaluation of Ketoprofen Buccal Tablets

Formulation Development and Evaluation of Ketoprofen Buccal Tablets

... Ketoprofen buccal tablets were manufactured by both direct compression method and wet granulation method using different levels and combinations of the polymers HPMC K4M, K100 and ...Ketoprofen buccal ... See full document

98

FORMULATION DEVELOPMENT AND EVALUATION OF CANDESARTAN BUCCAL TABLETS

FORMULATION DEVELOPMENT AND EVALUATION OF CANDESARTAN BUCCAL TABLETS

... All the tablets are having bevelled edged flat surface in round shape with white colour. Average weight of the tablets was in the range of 97-106 mg. Thickness of tablets was in the range of 4.18- 5.32 mm. Hardness of ... See full document

6

FORMULATION, DEVELOPMENT AND EVALUATION OF FLOATING BILAYERED TABLETS OF VENLAFAXINE HCL

FORMULATION, DEVELOPMENT AND EVALUATION OF FLOATING BILAYERED TABLETS OF VENLAFAXINE HCL

... tablet formulation, certain requirements such as sufficient mechanical strength and desired drug release profile must be ...consolidation. Venlafaxine Hydrochloride is an orally active serotonin ... See full document

10

OPTIMIZATION AND EVALUATION OF METOCLOPRAMIDE HCl AS MUCOADHESIVE BUCCAL PATCH

OPTIMIZATION AND EVALUATION OF METOCLOPRAMIDE HCl AS MUCOADHESIVE BUCCAL PATCH

... the buccal region has rich blood supply and relative permeability that offers an attractive route for drug administration into the systemic ...involved formulation of metoclopramide HCl as bilayer ... See full document

21

 FORMULATION AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE MUCOADHESIVE BUCCAL TABLETS

 FORMULATION AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE MUCOADHESIVE BUCCAL TABLETS

... metabolism. Buccal delivery system involves the administration of the desired drug through the buccal mucosal membrane lining of the oral ...Moreover buccal drug absorption can be promptly terminated ... See full document

6

Formulation and Evaluation of Sustained release tablets of Venlafaxine HCl

Formulation and Evaluation of Sustained release tablets of Venlafaxine HCl

... the development of sustained drug delivery ...of venlafaxine HCl using carbopol as rate controlling polymer has been ...of venlafaxine HCl can be efficiently prepared by wet granulation ... See full document

5

FORMULATION AND EVALUATION OF CHITOSAN BASED BUCCAL PATCH OF GRANISETRON HYDROCHLORIDE

FORMULATION AND EVALUATION OF CHITOSAN BASED BUCCAL PATCH OF GRANISETRON HYDROCHLORIDE

... The buccal route was chosen because of its good accessibility, robustness of epithelium, facile removal of the dosage form, relatively low enzymatic activity and natural clearance mechanism for elimination of the ... See full document

11

FORMULATION AND OPTIMIZATION OF THERMOREVERSIBLE IN-SITU GEL OF VENLAFAXINE HCl

FORMULATION AND OPTIMIZATION OF THERMOREVERSIBLE IN-SITU GEL OF VENLAFAXINE HCl

... the development of new generations of polymers based on pH or thermal responsiveness or modified existing polymers having improved bioadhesive or permeation-enhancing ...a formulation of Venlafaxine ... See full document

21

 FORMULATION AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE BUCCAL PATCHES

 FORMULATION AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE BUCCAL PATCHES

... formulate Venlafaxine hydrochloride buccal patches using sodium alginate along with two other mucoadhesive polymers, CMC and ...from buccal patches for long time, if buccal patches are ... See full document

5

 FORMULATION AND EVALUATION OF MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL

 FORMULATION AND EVALUATION OF MUCOADHESIVE MICROSPHERES OF VENLAFAXINE HCL

... are made from the biodegradable polymers in sustained drug delivery. Recently, dosage forms that can precisely control the release rates and target drugs to a specific body site have made an enormous impact in the ... See full document

6

DESIGN AND IN VITRO EVALUATION OF CONTROLLED RELEASE TRI LAYER VENLAFAXINE HCL TRANSDERMAL PATCH

DESIGN AND IN VITRO EVALUATION OF CONTROLLED RELEASE TRI LAYER VENLAFAXINE HCL TRANSDERMAL PATCH

... optimized formulation by using a modified Franz diffusion cell (50 ml) across a dialysis membrane 50 KD using phosphate buffer pH ...transdermal patch was placed in intimate contact with the dialysis ... See full document

7

DEVELOPMENT AND EVALUATION OF MUCOADHESIVE BUCCAL PATCH

DEVELOPMENT AND EVALUATION OF MUCOADHESIVE BUCCAL PATCH

... on buccal patch overlying moist ...till patch separates from mucosal ...separate patch from ...new patch of same formulation is used for each reading to get reproducible multiple ... See full document

13

FORMULATION AND EVALUATION OF THE SUCKABLE CHEWABLE MEDICATED LOLLIPOPS OF VENLAFAXINE Hcl

FORMULATION AND EVALUATION OF THE SUCKABLE CHEWABLE MEDICATED LOLLIPOPS OF VENLAFAXINE Hcl

... flavoring agent, coloring agent, opacifiers & stabilizing agent. Lo L ol ll li ip po op ps s are the flavored medicated dosage forms intended to be sucked and held in the mouth or pharynx containing one or more ... See full document

12

Design and Characterization of Mucoadhesive Buccal Patches of Tramadol Hydrochloride

Design and Characterization of Mucoadhesive Buccal Patches of Tramadol Hydrochloride

... The buccal route as an alternative to other traditional method of systemic drug administration is a subject of growing interest because of numerous advantages. It is well known that the absorption of therapeutic ... See full document

156

 PHARMACOKINETIC AND BIOEQUIVALENCE COMPARISON BETWEEN EXTENDED RELEASE CAPSULES OF VENLAFAXINE HYDROCHLORIDE 150MG: AN OPEN LABEL, BALANCED, RANDOMIZED-SEQUENCE, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY IN HEALTHY INDIAN MALE VOLUNTEERS

 PHARMACOKINETIC AND BIOEQUIVALENCE COMPARISON BETWEEN EXTENDED RELEASE CAPSULES OF VENLAFAXINE HYDROCHLORIDE 150MG: AN OPEN LABEL, BALANCED, RANDOMIZED-SEQUENCE, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY IN HEALTHY INDIAN MALE VOLUNTEERS

... for venlafaxine and ODV, respectively, has been reported 32-33 ...of venlafaxine occurs primarily via CYP2D6 and CYP3A4 (cytochrome P-450 ...of venlafaxine and ODV are ...of venlafaxine and ... See full document

8

Show all 10000 documents...